Preterm birth

Data-Science-Powered Research by Seattle Children's and Microsoft Shows Promise of Predicting SIDS and Other Causes of Sudden Death

Retrieved on: 
Thursday, March 28, 2024
Gene, Sudden death, Herbal cigarette, SIDS, Learning, Medical genetics, Child, Infant, Electronic cigarette, Oxygen, Rutgers University, Research institute, Microsoft, Partnership, Risk, International, Pediatrics, Death, Fatality, Seattle Children's, Preterm birth, Database, American Journal, Research, AI, University, Pregnancy, DRS, Cardiac arrest, Hypoxia, Genetic testing, Developing Story, Mortality, SUID, Doctor of Philosophy, Life, Smoking, Summit, Pacific Northwest, Medical device

The event was sponsored by The Center for Integrative Brain Research at Seattle Children's and Microsoft AI for Good Lab.

Key Points: 
  • The event was sponsored by The Center for Integrative Brain Research at Seattle Children's and Microsoft AI for Good Lab.
  • Among the many topics attendees discussed was groundbreaking new research that suggests genetic testing at birth may hold the promise of detecting SIDS risk — and potentially other causes of sudden death later in life.
  • The Aaron Matthew SIDS Research Foundation funds the database, which is maintained and managed at Seattle Children's Research Institute.
  • "Scientific research sometimes leads to surprises," said Jan-Marino Ramirez , PhD, Director of the Center for Integrative Brain Research at Seattle Children's.

HER Foundation's Dr. Marlena Fejzo Was Named to TIME's Annual Women of the Year List, Recognizing Extraordinary Leaders Fighting for a More Equal World

Retrieved on: 
Tuesday, March 12, 2024
HER, Mother, HG, Preterm birth, Mutation, BJOG, TIME, Entrepreneurship, Woman, Partnership, Hyperemesis gravidarum, Risk, Genetic epidemiology, Hospital, University, Pregnancy, Nausea, Morning sickness, HER Foundation, Water, Placenta, Chief, Vomiting, PTSD, Nature Communications, Pre-eclampsia, Nursing

PORTLAND, Ore., March 12, 2024 /PRNewswire/ -- TIME named Dr. Marlena Fejzo to its annual TIME Women of the Year list, recognizing extraordinary leaders fighting for a more equal world.

Key Points: 
  • PORTLAND, Ore., March 12, 2024 /PRNewswire/ -- TIME named Dr. Marlena Fejzo to its annual TIME Women of the Year list, recognizing extraordinary leaders fighting for a more equal world.
  • "I am truly honored to be recognized for my research on hyperemesis gravidarum (HG).
  • Dr. Fejzo will be presenting her research at the International Colloquium on Hyperemesis Gravidarum in Ventura (LA), California on November 6-7, 2024.
  • HER Foundation offers innovative clinical resources that improve the care and outcomes of those suffering from HG.

NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, March 11, 2024
Research, GDF15, PSC, Part, Vomiting, Pregnancy, MSS, Liver, Atlas, Preterm birth, NGM, LAIR1, Nausea, Hospital, ILT3, GFRAL, Food and Drug Administration, NASH, Therapy, Woman, Toxicology, Liver disease, CRC, Cirrhosis, Biomarker, Place of birth, Colorectal cancer, Agreement, Acquisition, Plan, FGF19, AASLD, FDA, Food, Weight loss, Primary sclerosing cholangitis, Pembrolizumab, Dehydration, Bile, Hyperemesis gravidarum, HG, Patient, Pre-eclampsia, Malnutrition, Pharmaceutical industry

--On February 26, 2024, announced that it had entered into the Agreement and Plan of Merger with Atlas Neon Parent, Inc., and Atlas Neon Merger Sub, Inc.--

Key Points: 
  • The combination of NGM707 and pembrolizumab was generally well-tolerated at all four doses (200, 600, 1200, 1800 mg) of NGM707.
  • Additional details can be found in NGM Bio’s recent filings with the United States Securities and Exchange Commission (SEC).
  • NGM Bio anticipates that the Offer and the Merger contemplated under the Merger Agreement will be consummated in the second quarter of 2024.
  • If the Merger is effected, NGM Bio’s common stock will be delisted from The Nasdaq Stock Market LLC and NGM Bio will be privately held.

Dr. Jose Villar Wins 2024 March of Dimes Agnes Higgins Award in Maternal-Fetal Nutrition

Retrieved on: 
Tuesday, February 20, 2024
Woman, Body composition, Microcephaly, Diet, Randomized controlled trial, Pregnancy, Obesity, Growth, Fetus, PAS, Life, Stanford University, Health, University, Mother, World Health Organization, Hypertension, Medicine, Infant, Pre-eclampsia, University of Oxford, Breast milk, CDC, Preterm birth, WHO, Research, Dietary supplement

ARLINGTON, Va., Feb. 20, 2024 /PRNewswire/ -- Dr. Jose Villar, a University of Oxford Professor has been named the 2024 recipient of the March of Dimes Agnes Higgins Award in Maternal-Fetal Nutrition. Dr. Villar, a Professor of Perinatal Medicine at Oxford's Nuffield Department of Women's and Reproductive Health and the former Coordinator of Maternal and Perinatal Health at the World Health Organization (WHO) has spent more than a half century researching the effect of maternal nutrition on the health, growth, and development of babies. The award will be presented to Dr. Villar at the annual meeting of the Pediatric Academic Societies (PAS) on May 4 in Toronto, Canada.

Key Points: 
  • Prominent Oxford scientist led studies on fetal growth, newborn size, and preterm postnatal growth
    ARLINGTON, Va., Feb. 20, 2024 /PRNewswire/ -- Dr. Jose Villar, a University of Oxford Professor has been named the 2024 recipient of the March of Dimes Agnes Higgins Award in Maternal-Fetal Nutrition.
  • The award will be presented to Dr. Villar at the annual meeting of the Pediatric Academic Societies (PAS) on May 4 in Toronto, Canada.
  • They present a universal blueprint for healthy growth and development from early gestation to two years of age.
  • That is the challenge ahead, and I couldn't be prouder to continue it alongside March of Dimes."

Giving birth in Sweden: outcomes are worse for foreign-born mothers

Retrieved on: 
Monday, February 12, 2024
Woman, Research, Infection, Language, Pregnancy, Communication, Stillbirth, Mother, COVID, Map, Child, Preterm birth, Mortality, Birth control

Unfortunately, these achievements don’t extend to foreign-born mothers who face higher risks for all forms of negative pregnancy outcomes.

Key Points: 
  • Unfortunately, these achievements don’t extend to foreign-born mothers who face higher risks for all forms of negative pregnancy outcomes.
  • Foreign-born mothers reported higher rates of infection, intensive care admission, preterm birth, underweight babies and stillbirths compared with Swedish-born mothers.
  • The evidence-based guidelines used in the Swedish healthcare system are backed by several high-quality registers that document patient outcomes at the population level.
  • Of the few variables collected, country of birth is one and job status is the other.
  • This means that the most valuable tool available to maternal healthcare professionals is essentially impaired from identifying how health inequities can affect birth outcomes.

Language barriers

  • Communication barriers due to a lack of proficiency in the Swedish language in foreign-born mothers is a large challenge in this regard.
  • In high-risk situations, like during an emergency caesarean section, such communication barriers may be critical and can even cost lives.
  • Also, there is limited understanding of how these language barriers affect foreign-born mothers’ overall understanding of the care they are receiving and their experiences of the quality of care provided.


Mehreen Zaigham receives funding from the Swedish Research Council Grant 2022–00208.

Preterm Births Linked to 'Hormone Disruptor' Chemicals May Cost United States Billions

Retrieved on: 
Tuesday, February 6, 2024
ECHO, University, Columbia University, NYU, Cosmetics, Phthalate, Bangladesh Technical Education Board, Champaign–Urbana metropolitan area, Wayne State University, Lancet, NYU Langone Health, Food, National Institutes of Health, DEHP, MPH, Emory University, Woman, Johns Hopkins University, Population health, MPP, Blood, DIDP, Northeastern University, Infant, Risk, Doctor of Philosophy, Rutgers University, Cancer, Gestational age, Triangle Park (Quezon City), Racism, Mother, Research, Obesity, Preterm birth, RTI International, The Lancet, Pregnancy, Doctor of Science, Dartmouth College, Diabetes, Pennsylvania State University, Urine, Hormone, Achievement Medal, Pediatrics, Dietary supplement

Then, the team looked for associations between these metabolite levels and preterm births.

Key Points: 
  • Then, the team looked for associations between these metabolite levels and preterm births.
  • "Otherwise, investigators are likely going to find the same study results in another few years about the next group of chemicals used as replacements."
  • California, among a few states, has banned some use of phthalates in consumer products, as have European Union member states.
  • Trasande cautions that further research is needed to better understand the specific mechanisms behind the link between phthalate exposure and preterm birth.

Autoimmune Disease and Pregnancy: ISB Study Challenges Prevailing Wisdom, Unveils Nuances

Retrieved on: 
Wednesday, January 31, 2024
Other Health, Research, Consumer, Healthcare Reform, Parenting, Science, Baby, Maternity, COVID-19, Other Science, Health, Diabetes, Public Policy, Government, Multimedia, Multiple sclerosis, Sarcoidosis, ISB, Mother, Health information management, Vasculitis, MD, Preterm birth, Inflammatory bowel disease, Antiphospholipid syndrome, Patient, Rheumatoid arthritis, Spondyloarthropathy, Cohort (statistics), Providence, Lupus, Hypertension, Pregnancy, Autoimmunity, Thought, Risk, Psoriatic arthritis, Psoriasis, Autoimmune disease, Gestational age, Birth control

View the full release here: https://www.businesswire.com/news/home/20240131144327/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240131144327/en/
    In a just-published study in the journal Lancet eClinical Health , researchers at the Institute for Systems Biology (ISB) and Providence showed nuanced pregnancy outcomes for pregnant individuals with autoimmune disease.
  • Each type of autoimmune disease is different, each person has their own medical history, and risk may change over the course of pregnancy.
  • This study highlights the importance of taking comorbidities into consideration,” said ISB Associate Professor Jennifer Hadlock, MD , who led the study.
  • “These results can help reshape discussions surrounding autoimmune disease and pregnancy, and bring fresh perspective to a traditionally understudied area in research,” Hadlock said.

Bloomlife Announces FDA Clearance of Bloomlife MFM-Pro

Retrieved on: 
Tuesday, January 16, 2024
Entrepreneurship, Woman, Health, Life, SAN, Partnership, Clio Awards, Mortality, Food, Pregnancy, WHO, FDA, Preterm birth

SAN FRANCISCO, Jan. 16, 2024 /PRNewswire/ -- Bloomlife, the award winning maternal health company, has received clearance from the US Food and Drug Administration (FDA) for Bloomlife MFM-Pro, their first maternal and fetal monitoring device.

Key Points: 
  • SAN FRANCISCO, Jan. 16, 2024 /PRNewswire/ -- Bloomlife, the award winning maternal health company, has received clearance from the US Food and Drug Administration (FDA) for Bloomlife MFM-Pro, their first maternal and fetal monitoring device.
  • The FDA clearance represents a major milestone in their journey transitioning from consumer to medical markets.
  • Since its inception Bloomlife has been at the forefront of maternal health innovation.
  • The FDA clearance of Bloomlife MFM-Pro marks an important milestone by cementing our transition from consumer to medical markets", says Eric Dy PhD, Co-Founder and CEO of Bloomlife.

NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need

Retrieved on: 
Tuesday, January 9, 2024
Bile, Woman, Hyperemesis gravidarum, Research, Biology, Hospital, Weight loss, MSS, FRS, Hepatology, University, ILT3, Liver disease, FGF19, GFRAL, LAIR1, Liver, Doctor of Philosophy, NASH, CRC, Pembrolizumab, Trial of the century, Neoplasm, NGM, SAN, PRS, Public health, Genetic epidemiology, Preterm birth, Vomiting, Cirrhosis, DCR, Dehydration, AASLD, Immunotherapy, Place of birth, Medicine, Pregnancy, Pre-eclampsia, Therapy, ELF, Patient, Bile acid malabsorption, Fibrosis, Nausea, Alkaline phosphatase, PSC, Gastrointestinal disease, CRN, IBS-D, Malnutrition, FDA, Biomarker, Pharmaceutical industry

NGM Bio also outlined its strategy to evolve clinical development of its product candidates aldafermin and NGM120 to focus on rare conditions characterized by significant unmet need.

Key Points: 
  • NGM Bio also outlined its strategy to evolve clinical development of its product candidates aldafermin and NGM120 to focus on rare conditions characterized by significant unmet need.
  • Recent landmark genetic research confirmed the link between this rare, devastating condition experienced during pregnancy to higher levels of GDF15.
  • Given our deep expertise in GDF15 biology, we believe we are well positioned to potentially pursue this indication for NGM120.
  • NGM Bio previously reported data from a randomized, double-blind, placebo-controlled Phase 2 study of aldafermin for the treatment of PSC.

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study

Retrieved on: 
Wednesday, December 13, 2023
Risk, NICHD, Woman, Estradiol, FDA, Trial of the century, SAN, Doctor of Philosophy, Award, Preterm birth, Clinical trial, Death, NIH, IVR, Pharmaceutical industry

SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it received a Notice of Award of a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a division of the National Institutes of Health (NIH). The award will support the clinical development of Daré’s novel, investigational intravaginal ring (IVR), DARE-PTB1. DARE-PTB1 is designed to deliver bio-identical progesterone continuously for up to a 14-day period and is being developed as a treatment for the prevention of preterm birth in at-risk women, for which there are currently no FDA-approved treatments.

Key Points: 
  • The award will support the clinical development of Daré’s novel, investigational intravaginal ring (IVR), DARE-PTB1.
  • “Daré is committed to addressing persistent unmet needs in women’s health and preterm birth is a large category that could benefit from new treatment options to protect women and babies.
  • The content of this press release is solely the responsibility of Daré Bioscience, Inc. and does not necessarily represent the official views of the National Institutes of Health.
  • This press release discusses a project that will be supported by the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health under Award Number 4R44HD101169-02.